Metabolic and Clinical Outcomes of Combined Pitavastatin and Valsartan Therapy in Patients With Acute Myocardial Infarction: A Multicenter Prospective Observational Study

Figures

• 

  Fig. 1. Study flowchart. Of the 852 patients enrolled, 836, 698, and 564 were included in the safety analysis set, full analysis set, and per protocol analysis set, respectively.

• 

  Fig. 2. Changes in fasting blood glucose and HbA1c levels. (A) Mean fasting blood glucose levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 49 at baseline and 10 at week 48; pitavastatin 4 mg group, 326 at baseline and 92 at week 48. (B) Mean HbA1c levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 56 at baseline and 9 at week 48; pitavastatin 4 mg group, 264 at baseline and 92 at week 48. HbA1c, glycated hemoglobin.

• 

  Fig. 3. Changes in lipid profile levels. (A) Mean total cholesterol levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 65 at baseline and 10 at week 48; pitavastatin 4 mg group, 381 at baseline and 104 at week 48. (B) Mean triglyceride levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 63 at baseline and 13 at week 48; pitavastatin 4 mg group, 356 at baseline and 105 at week 48. (C) Mean HDL cholesterol levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 64 at baseline and 13 at week 48; pitavastatin 4 mg group, 355 at baseline and 104 at week 48. (D) Mean LDL-cholesterol levels by group at baseline and week 48 in the per protocol set (n=564). Numbers analyzed: pitavastatin 2 mg group, 64 at baseline and 13 at week 48; pitavastatin 4 mg group, 352 at baseline and 103 at week 48. HDL, high-density lipoprotein; LDL, low-density lipoprotein.